# Capecitabine

## Capecitabine 500mg

| TAH Drug Code      | [**OCAP5**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OCAP5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Colon cancer, Adjuvant therapy, Duke's Stage C, when treatment with a fluoropyrimidine alone is preferred. Metastatic breast cancer, metastatic colorectal cancer, 1-line therapy when treatment with a fluoropyrimidine alone is preferred.                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Adjuvant treatment is recommended for a total of 6 months (8 cycles) [Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, Dukes’ C colon cancer (adjuvant treatment)] 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period given as 3-week cycles for a total of 8 cycles (24 weeks) [Metastatic Breast Cancer] Monotherapy: 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period given as 3-week cycles; Combination: 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period, combined with docetaxel at 75 mg/m2 as a 1-hour intravenous infusion every 3 weeks. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Known hypersensitivity to capecitabine, fluorouracil, or any component of the formulation; severe renal impairment (CrCl <30 mL/minute). Canadian labeling: Additional contraindications (not in the US labeling): Known complete absence of dihydropyrimidine dehydrogenase (DPD) activity; concomitant administration with sorivudine or chemically related analogues (eg, brivudine).                                                                                                                                                                                                                            |
| Adverse Effects    | GI disturbances; hand-foot syndrome, alopecia, pruritus, rash; fatigue, pyrexia, lethargy, asthenia; dizziness, taste disturbance; anorexia; conjunctivitis; neutropenia. Dermatologic: Dermatitis (27% to 37% ) Gastrointestinal: Abdominal pain, Constipation, Loss of appetite, Nausea, Stomatitis, Vomiting Other: Fatigue                                                                                                                                                                                                                                                                                      |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

